Sucampo Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2013 Financial and Operating Results

Sucampo Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2013
Financial and Operating Results

  Sucampo to Begin Co-promotion of AMITIZA for Opioid-Induced Constipation;
                     Revises RESCULA Commercial Strategy

           Company to Host Conference Call Today at 5:00 pm Eastern

Highlights

  *Sucampo Revenue Grew 39.6% Year-Over-Year for the Nine Months of 2013
  *U.S. AMITIZA^® (lubiprostone) Net Sales, As Reported By Our Partner,
    Increased 3.5% Year-Over-Year for the Nine Months of 2013
  *Sucampo revenue from sales of AMITIZA in Japan grew 58.2% in third as
    compared to second quarter of the year
  *Sucampo Raises 2013 Earnings Guidance, Excluding Special Items
  *Sucampo Announces Commercial Strategy Changes

    *Sucampo and partner Takeda Pharmaceuticals U.S.A. Inc (Takeda) agree to
      increase promotional effort for AMITIZA for non-cancer opioid-induced
      constipation (OIC)
    *RESCULA^® (unoprostone isopropyl) promotional costs will be reduced by
      approximately 75% versus current spend

BETHESDA, Md., Nov. 5, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc.
("Sucampo") (Nasdaq:SCMP), a global biopharmaceutical company with products
available in the United States (U.S.), Japan and Europe, today reported its
consolidated financial results for the third quarter and nine months ended
September 30, 2013.

Sucampo raised its full year 2013 earnings guidance to $3.0 to $5.0 million
net income, excluding special items, versus previous guidance of break-even.
During the third quarter of 2013, Sucampo recorded a non-cash write-off of its
RESCULA inventory and samples of $4.5 million to reflect excess quantities of
dated product. Details of the write-off are discussed in the Cost of Goods
Sold and Operating Expenses sections below.

                                                   Three Months  Nine Months
                                                  Ended         Ended
                                                   September 30, September 30,
(In thousands, except per share data)              2013          2013
Total revenues                                     $21,163     $65,104
GAAP Diluted EPS                                   0.03         0.10
Non-GAAP Diluted EPS that exclude RESCULA          0.09         0.16
inventory/samples non-cash write-off^1
GAAP net income^2                                  1,291        4,266
Non-GAAP net income that excludes RESCULA          4,007        6,982
inventory/samples non-cash write-off^1, 2

^1. Sucampo is providing certain 2013 non-GAAP information that excludes
certain items because of the nature of these items and the impact they have on
the analysis of underlying business performance and trends. Management
believes that providing this information enhances investors' understanding of
Sucampo's performance. This information should be considered in addition to,
but not in lieu of, information prepared in accordance with GAAP.

^2. Net income is attributable to Sucampo Pharmaceuticals, Inc. on a
consolidated basis.

Sucampo also announced that it is exercising the co-promotion option in its
commercialization agreement with Takeda and will begin co-promoting AMITIZA
for OIC in adults with chronic, non-cancer pain in the first quarter of next
year. Sucampo's AMITIZA co-promotion will provide incremental selling
resources in addition to Takeda's current selling efforts, and Takeda will
reimburse Sucampo based on details to healthcare prescribers. In addition,
Sucampo announced changes to its RESCULA commercialization strategy to improve
RESCULA profitability by significantly decreasing sales and marketing
expenses. Sucampo will continue, but significantly decrease the amount of,
in-person sales calls for RESCULA, and will use a contract sales force to
focus its detailing on current prescribers. Sucampo will also use a limited
mix of inside sales and other promotional tactics, including digital, to reach
the current non-prescriber base in an effort to increase prescribers and
sales.

"Sucampo revenue grew approximately 40% year-over-year for the first nine
months of 2013, driven by continued growth of AMITIZA in recently launched
markets, as well as the new OIC indication which yielded us a $10 million
milestone from our US partner. Specifically in the US, the 3.5% year-to-date
net sales increase for AMITIZA in the U.S. demonstrates that the constipation
drug market continues to expand," said Ryuji Ueno, M.D., Ph.D., Ph.D.,
Chairman, Chief Executive Officer, and Chief Scientific Officer of Sucampo.
"More than 200 million prescriptions for opioids are written in the U.S.
annually, with a significant portion of them for non-cancer pain. We believe
that the OIC indication, for which AMITIZA is the only oral treatment
approved, will be a significant driver of future AMITIZA growth. We also made
progress this quarter in our globalization efforts for AMITIZA. This year thus
far, we have added $10 million in incremental revenue to our topline through
Japan sales of AMITIZA, and we are seeing increasing sales from the product in
Switzerland. In addition, we progressed our late-stage pipeline assets in the
quarter with the initiation of our pivotal liquid formulation study of
lubiprostone in adults with chronic idiopathic constipation. Finally, we
announced the completion of patient enrollment by our development partner
R-Tech Ueno Ltd. in a phase 3 trial of unoprostone isopropyl in retinitis
pigmentosa."

Stan Miele, President, Sucampo Pharma Americas, LLC and Senior Vice President
of Sales and Marketing for Sucampo, added, "Sucampo is investing incremental
selling resources in OIC to accelerate the growth of AMITIZA. AMITIZA
continues to grow in the U.S., particularly in new OIC targets, and we believe
that Sucampo can fuel additional growth by investing in reaching even more OIC
targets. At the same time, while we believe in the value of RESCULA for
patients suffering from glaucoma and ocular hypertension, we are making
changes to our RESCULA commercialization strategy to better balance investment
and revenue."

Third Quarter and To Date Operational Highlights –

  *U.S. net sales of AMITIZA, as reported to us by our partner, Takeda, for
    royalty calculation purposes, increased 1.4% to $72.5 million for the
    third quarter of 2013, compared to $71.5 million in the same period of
    2012. U.S. net sales of AMITIZA, as reported to us by our partner, Takeda,
    for royalty calculation purposes, increased 3.5% to $204.1 million for the
    first nine months of 2013, compared to $197.2 million in the same period
    for 2012.
  *Sucampo continued its sales growth in the Japanese market, reporting a
    58.2% increase in AMITIZA product sales revenue of $5.2 million compared
    to the second quarter of 2013.
  *Sucampo showed sequential quarterly sales growth in Switzerland for
    AMITIZA for chronic idiopathic constipation (CIC).
  *Sucampo continued partnership discussions for strategic alliances for
    AMITIZA for global markets outside of the U.S. and Japan, including
    Europe, China, Latin America and other emerging markets.
  *In October, Sucampo announced the initiation of a pivotal trial of a
    liquid formulation of lubiprostone 24 mcg twice daily in adults.
  *Sucampo continued its preparation for initiation of the pivotal phase 3
    program in pediatric functional constipation.
  *Sucampo recently announced that its development partner, R-Tech Ueno Ltd.,
    completed patient enrollment of a phase 3 clinical trial for unoprostone
    isopropyl for RP in Japan. A substantial portion of the development costs
    for the program are being funded by the Japan Science and Technology
    Agency. Sucampo has rights to the clinical data for potential filing in
    Europe and the U.S., where unoprostone isopropyl has orphan drug
    designation, and will decide on our path forward assuming the Japanese
    trial is successful.
  *In October, Sucampo announced the publication in the Journal of Pediatric
    Gastroenterology & Nutrition of a manuscript on pediatric functional
    constipation in children based on an open-label study on lubiprostone in
    children and adolescents with functional constipation. This study
    demonstrated that lubiprostone is efficacious and well-tolerated in this
    patient population.
  *Sucampo initiated a phase 1b trial for cobiprostone for the treatment of
    oral mucositis in October.
  *Progress continued in our search for a new Chief Executive Officer. As
    Sucampo previously announced, Ryuji Ueno, M.D., Ph.D., Ph.D., will focus
    solely on his role as Chief Scientific Officer and driving the overall
    scientific direction of the company, once a new CEO is named.

2013 Value Drivers:

Sucampo is pursuing the following value drivers in 2013, and, has already
achieved eight (denoted with a +) of the thirteen thus far this year:

AMITIZA

  U.S.

  + Achieved approval of the OIC indication for AMITIZA in the U.S.

  + Received a $10.0 million milestone payment from Takeda upon the approval
  and first commercial sale of AMITIZA for OIC in the U.S.

  Global

    *Engaging in discussions for strategic alliances for AMITIZA for new
      indications and new territories outside of the U.S., including Europe,
      China, Latin America and other emerging markets

  Japan

  + Strong sales growth of AMITIZA

  Europe

  + Completed in the first quarter of 2013 the submission for regulatory
  approval in the United Kingdom (U.K.) and Switzerland of AMITIZA for the
  treatment of OIC. We will continue to work with regulatory authorities to
  achieve approval

  + Began active marketing of AMITIZA for CIC in Switzerland

  *Submission of filings via the mutual recognition procedure (MRP) for
    AMITIZA in other European markets
    
  *Filing for National Institute for Health and Care Excellence endorsement
    for CIC and OIC and launching AMITIZA in the U.K.

RESCULA

  + Launched RESCULA in February in the U.S.

Pipeline

  Lubiprostone

    *Achieve First Patient First Visit in our AMITIZA phase 3 trial for
      pediatric functional constipation in the second half of 2013

  *Oral Mucositis

  + Completed our oral mucositis phase 1a trial for cobiprostone in the second
  quarter of 2013

  + Initiated a phase 1b trial for cobiprostone on October 31

  Spinal Stenosis

    *Complete our spinal stenosis phase 2a, double-blind, placebo-controlled
      trial for our intravenous ion channel activator for lumbar spinal
      stenosis

Financial Results for the Quarter

For the third quarter of 2013, Sucampo reported total revenue of $21.2 million
compared to $15.5 million for the same period in 2012, a growth of
approximately 36.6%. The key components of revenue for the 2013 third quarter
included R&D revenue of $2.0 million, product royalty revenue of $13.6
million, product sales revenue of $5.4 million and co-promotion revenue of
nil, which compare to $0.7 million, $13.9 million, nil and $0.7 million,
respectively, in the same period of 2012.

For the first nine months of 2013, Sucampo reported total revenue of $65.1
million compared to $46.6 million for the same period in 2012, a growth of
approximately 39.6%. The key components of revenue for the 2013 nine months
period included R&D revenue of $16.3 million, product royalty revenue of $37.3
million, product sales revenue of $11.0 million, and co-promotion revenue of
$0.1 million, which compare to $6.4 million, $36.5 million, nil and $3.3
million, respectively, in the same period of 2012.

U.S. net sales of AMITIZA, as reported to us by our partner, Takeda, for
royalty calculation purposes increased 1.4% to $72.5 million for the third
quarter of 2013, compared to $71.5 million in the same period of 2012. U.S.
net sales of AMITIZA, as reported to us by our partner, Takeda, for royalty
calculation purposes, increased 3.5% to $204.1 million for the nine months of
2013, compared to $197.2 million in the same period of 2012.

Cost of Goods Sold

Cost of goods sold relates to purchase and distribution costs of the Company's
products sold by the Company, including changes in inventory provisions for
excess and obsolete inventory. Cost of goods sold were $6.3 million for the
third quarter of 2013, compared to nil for the third quarter of 2012, an
increase of $6.3 million. Cost of goods sold were $9.5 million for the nine
months of 2013, compared to nil for the prior year period, an increase of $9.5
million. The increase in cost of goods sold relates to drug product sales of
AMITIZA in Japan and Switzerland and RESCULA in the U.S. During the third
quarter of 2013, Sucampo recorded a non-cash write-off of its RESCULA
inventory of $3.0 million to reflect excess quantities of dated product. The
excess inventory was largely a result of the necessity to pre-order product in
advance of FDA approval due to a planned change in manufacturing facility and
lower than anticipated sales within the useful life of the dated product.

Operating Expenses

R&D expenses, comprised of expenses for clinical development of the
lubiprostone pediatric indication and liquid formulation, phase 1 trial
expenses for oral mucositis, and clinical development expenses for our lumbar
spinal stenosis program, were $4.5 million for the third quarter of 2013,
compared to $5.6 million for the same period of 2012. The decrease was
primarily due to the lower costs associated with our unoprostone isopropyl
development program and a lower provision associated with our Numab
collaboration. For the first nine months of 2013, R&D expenses were $14.5
million, compared to $14.2 million for the prior year period. The increase in
expenses was primarily due to the higher costs associated with clinical
development of our phase 2a trial for lumbar spinal stenosis and higher
indirect costs including regulatory fees, partially offset by lower costs on
our unoprostone isopropyl development program.

G&A expenses were $5.4 million for the third quarter of 2013, compared to $7.3
million for the third quarter of 2012, a decrease of $1.8 million or 25.0%.
G&A expenses were $18.6 million for the nine months of 2013, compared to $22.6
million for the prior year period, a decrease of $4.0 million or 17.5%. For
both periods, the decrease in G&A expense was primarily due to lower legal,
consulting and other professional expenses as a result of the conclusion of
certain legal matters in 2012, as well as expense reductions from 2013
productivity initiatives. These decreases were partially offset by a $0.3
million and $1.9 million increase in pharmacovigilance costs associated with
the launch of AMITIZA in Japan for the third quarter and nine month period,
respectively. Excluding the impact of pharmacovigilance costs, G&A expenses
decreased 29.2% in the third quarter and 26.1% during the first nine months of
2013.

Selling and marketing expenses were $6.0 million for the third quarter of
2013, compared to $4.3 million for the third quarter of 2012.Selling and
marketing expenses were $16.0 million for the nine months ended September 30,
2013 compared to $14.5 million for the prior year period.For both periods, the
increase in selling and marketing expenses relates primarily to launch costs
for RESCULA and a $1.5 million non-cash write-offrecorded for excess RESCULA
samples, partially offset by non-recurring pre-commercialization planning
activities for AMITIZA and RESCULA that occurred in 2012 that did not occur in
2013.

Income (Loss) from Operations

Loss from operations for the third quarter of 2013 was $1.0 million, compared
to a loss of $1.7 million for the same period in 2012. Income from operations
for the nine months ended September 30, 2013 was $6.5 million, compared to a
loss of $4.6 million for the prior year period.

Non-Operating Income (Expense)

Non-operating expense was $0.5 million for the third quarter of 2013, compared
to expense of $0.5 million for the same period in 2012. The third quarter of
2013 included a foreign exchange loss of $49,000 compared to a gain of $8,000
in the same period in 2012. Non-operating income was $0.4 million for the nine
months ended September 30, 2013, compared to expense of $0.9 million for the
same period in 2012. Non-operating expense for the nine months ended September
30, 2013, included a foreign exchange gain of $1.8 million, compared to a
foreign exchange gain of $0.7 million for the same period in 2012.

Net (Income) Loss

Net income for the third quarter was $1.3 million, compared to a net loss of
$5.9 million for the same period of 2012. Net income for the first nine months
of 2013 was $4.3 million, compared to a net loss of $8.7 million for the same
period of 2012.

Earnings Excluding Special Items

Net income excluding special items for the third quarter of 2013 was $4.0
million, or $0.09 per diluted share, compared to a net loss of $5.9 million,
or ($0.14) per diluted share, in the third quarter of 2012. Net income
excluding special items for the first nine months of 2013 was $7.0 million, or
$0.16 per diluted share, compared to a net loss of $8.7 million, or ($0.21)
per diluted share, in the first nine months of 2012.

Non-GAAP (generally accepted accounting principles) earnings per share (EPS)
for the third quarter and nine months ended September 30, 2013 of $0.09 and
$0.16, respectively, exclude RESCULA inventory and sample non-cash write-off
costs.

A reconciliation of GAAP to non-GAAP net income (loss) and EPS is provided in
the tables that follow.

                                                   Three Months  Nine Months
                                                  Ended         Ended
                                                   September 30, September 30,
(In thousands, except per share data)              2013          2013
EPS                                                              
GAAP Diluted EPS                                   $0.03       $0.10
Difference^3                                       $0.06       0.06
Non-GAAP Diluted EPS that exclude RESCULA          $0.09       0.16
inventory/samples non-cash write-off^1
Net income                                                      
GAAP net income^2                                  $1,291      $4,266
Difference                                         2,716        2,716
Non-GAAP net income that excludes RESCULA          4,007        6,982
inventory/samples non-cash write-off^1, 2
Increase in net income due to excluded items:
Net increase in income tax before taxes            $(4,527)    $(4,527)
Estimated income tax expense                       1,811        1,811
Increase in net income                            (2,716)      (2,716)

^3.Represents the difference between calculated GAAP EPS and calculated
non-GAAP EPS, which may be different than the amount calculated by dividing
the impact of the excluded items by the weighted-average shares for the
period.

Comprehensive Income (Loss)

Comprehensive income for the third quarter of 2013 was $1.1 million, compared
to a comprehensive loss of $6.1 million for the same period in 2012.
Comprehensive income for the nine months of 2013 was $3.9 million, compared to
comprehensive loss of $10.4 million for the same period in 2012.

Cash, Cash Equivalents, Restricted Cash and Marketable Securities

At September 30, 2013, cash, cash equivalents, restricted cash and investments
were $91.0 million, compared to $91.4 million at December 31, 2012. At
September 30, 2013, notes payable were $57.9 million, compared to $52.9
million at December 31, 2012, including current notes payable of $28.1 million
at September 30, 2013, and $19.1 million at December 31, 2012.

Stock Repurchase Plan

In September 2011, the Board of Directors (Board) authorized the repurchase of
our class A common stock under the previously approved repurchase plan, up to
an aggregate of $2.0 million. On November 2, 2012, the Board authorized the
increase of the program amount up to an aggregate of $5.0 million. During the
nine months of 2013, Sucampo repurchased 67,762 shares at a cost of $0.3
million. Since inception, we have repurchased approximately $2.3 million of
our common stock. We believe that the cumulative repurchases through the first
nine months of this year mitigate any dilutive effects of employee and others'
exercises of stock options during the same period. The repurchase program may
be used in the future to continue to address any such dilutive effects.

Future Guidance

Sucampo today increased its earnings guidance for 2013 and reaffirmed its
guidance for 2014. Sucampo now expects full year 2013 net income, excluding
special items, to be in the range of $3.0 million to $5.0 million, or $0.07 to
$0.12 per diluted share, versus previous guidance of approximately break-even.

Company to Host Conference Call Today

In conjunction with this second quarter financial and operating results press
release, Sucampo will host a conference call today at 5:00 pm Eastern. To
participate on the live call, please dial 866-318-8611 (domestic) or
617-399-5130 (international), and provide the participant passcode 61691134,
five to ten minutes ahead of the start of the call. A replay of the call will
be available within a few hours after the call ends. Investors may listen to
the replay by dialing 888-286-8010 (domestic) or 617-801-6888 (international),
with the passcode 75849618.

Investors interested in accessing the live audio webcast of the teleconference
may do so at http://investor.sucampo.com and should log on before the
teleconference begins in order to download any software required. The archive
of the teleconference will remain available for 30 days.

About lubiprostone (AMITIZA^®)

AMITIZA (lubiprostone) is a prostone, a locally acting chloride channel
activator, indicated for the treatment of CIC in adults and OIC in adults with
chronic, non-cancer pain (24 mcg twice daily) and for IBS-C (8 mcg twice
daily) in women 18 years of age and older in the U.S. In Japan, lubiprostone
(24 mcg twice daily) is indicated for the treatment of chronic constipation
(excluding constipation caused by organic diseases). In Switzerland,
lubiprostone (24 mcg twice daily) is indicated for the treatment of chronic
idiopathic constipation. In the U.K., lubiprostone (24 mcg twice daily) is
indicated for the treatment of chronic idiopathic constipation and associated
symptoms in adults.

About unoprostone isopropyl (RESCULA^®)

In 2009, Sucampo acquired development and commercialization rights to
unoprostone isopropyl throughout the world except in Japan, Korea, Taiwan and
the People's Republic of China. Unoprostone isopropyl 0.12% (trade named
RESCULA) first received marketing authorization in 1994 in Japan and was
subsequently approved in over 40 countries, including approval in 2000 by the
FDA. RESCULA (unoprostone isopropyl ophthalmic solution) 0.15% is indicated
for the lowering of intraocular pressure (IOP) in patients with open-angle
glaucoma or ocular hypertension in the U.S.

About Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc. is focused on the discovery, development and
commercialization of drugs based on ion channel activators knows as prostones.
Discovered by the company's scientific founder, prostones are naturally
occurring fatty acid metabolites with unique physiological activities. Sucampo
has two marketed products – AMITIZA and RESCULA – and a pipeline of
prostone-based product candidates in clinical development. A global company,
Sucampo is headquartered in Bethesda, Maryland, and has operations in the
United Kingdom, Switzerland and Japan. For more information, please visit
www.sucampo.com.

The Sucampo logo and the tagline, The Science of Innovation, are registered
trademarks of Sucampo AG.

AMITIZA is a registered trademark of Sucampo AG. RESCULA is a registered
trademark of R-Tech Ueno, Ltd, and has been licensed to Sucampo AG.

Follow us on Twitter (@Sucampo_Pharma). Follow us on LinkedIn (Sucampo
Pharmaceuticals).

Twitter LinkedIn

Sucampo Forward-Looking Statement

This press release contains "forward-looking statements" as that term is
defined in the Private Securities Litigation Reform Act of 1995. These
statements are based on management's current expectations and involve risks
and uncertainties, which may cause results to differ materially from those set
forth in the statements. The forward-looking statements may include statements
regarding product development, product potential, future financial and
operating results, and other statements that are not historical facts. The
following factors, among others, could cause actual results to differ from
those set forth in the forward-looking statements: the impact of
pharmaceutical industry regulation and health care legislation; Sucampo's
ability to accurately predict future market conditions; dependence on the
effectiveness of Sucampo's patents and other protections for innovative
products; the risk of new and changing regulation and health policies in the
U.S. and internationally and the exposure to litigation and/or regulatory
actions.

No forward-looking statement can be guaranteed and actual results may differ
materially from those projected. Sucampo undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new information,
future events, or otherwise. Forward-looking statements in this presentation
should be evaluated together with the many uncertainties that affect Sucampo's
business, particularly those mentioned in the risk factors and cautionary
statements in Sucampo's most recent Form 8-K and 10-K, which Sucampo
incorporates by reference.

Sucampo Pharmaceuticals, Inc.
Consolidated Statements of Operations and Comprehensive Income(unaudited)
(in thousands, except per share data)
                                                           
                          Three Months Ended    Nine Months Ended September
                           September 30,         30,
                          2013      2012        2013          2012
                                                           
Revenues:                                                   
Research and development   $2,027  $737      $16,288     $6,418
revenue
Product royalty revenue    13,595   13,890     37,271       36,521
Product sales revenue      5,378    --        10,994       --
Co-promotion revenue       --      730        61           3,253
Contract and collaboration 163      139        490          433
revenue
Total revenues             21,163   15,496     65,104       46,625
                                                           
Cost of goods sold         6,267    --        9,457        --
Gross profit               14,896   15,496     55,647       46,625
                                                           
Operating expenses:                                         
Research and development   4,474    5,615      14,528       14,202
General and administrative 5,440    7,256      18,635       22,598
Selling and marketing      6,026    4,278      15,967       14,474
Total operating expenses   15,940   17,149     49,130       51,274
                                                           
Income (loss) from         (1,044)  (1,653)    6,517        (4,649)
operations
Non-operating income                                        
(expense):
Interest income            20       68         63           118
Interest expense           (461)    (596)      (1,449)      (1,780)
Other income (expense),    (49)     8          1,776        727
net
Total non-operating income (490)    (520)      390          (935)
(expense), net
                                                           
Income (loss) before       (1,534)  (2,173)    6,907        (5,584)
income taxes
Income tax benefit         2,825    (3,776)    (2,641)      (3,112)
(provision)
Net income (loss)          $1,291  $(5,949)  $4,266      $(8,696)
                                                           
Net income (loss) per                                       
share:
Basic net income (loss)    $0.03   $(0.14)   $0.10       $(0.21)
per share
Diluted net income (loss)  $0.03   $(0.14)   $0.10       $(0.21)
per share
Weighted average common    41,863   41,678     41,644       41,697
shares outstanding - basic
Weighted average common
shares outstanding -       42,787   41,678     42,662       41,697
diluted
                                                           
Comprehensive loss:                                         
Net income (loss)          $1,291  $(5,949)  $4,266      $(8,696)
Other comprehensive income                                  
(loss):
Unrealized loss on
investments, net of tax    18       28         (16)         23
effect
Foreign currency           (253)    (175)      (387)        (1,767)
translation
Comprehensive income       $1,056  $(6,096)  $3,863      $(10,440)
(loss)



Sucampo Pharmaceuticals, Inc.
Consolidated Balance Sheets (unaudited)
(in thousands, except share data)                                
                                                                
                                                   September 30, December 31,
                                                   2013          2012
ASSETS:                                                          
                                                                
Current assets:                                                  
Cash and cash equivalents                           $39,911     $52,022
Investments, current                                15,263       6,035
Product royalties receivable                        13,595       14,175
Unbilled accounts receivable                        --          732
Accounts receivable, net                            2,694        1,360
Deferred tax assets, current                        1,273        874
Deferred charge, current                            673          673
Income taxes receivable                             2,013        --
Restricted cash, current                            26,141       15,113
Inventory                                           261          --
Prepaid expenses and other current assets           3,835        1,930
Total current assets                                105,659      92,914
                                                                
Investments, non-current                            7,259        14,408
Property and equipment, net                         1,278        1,540
Intangibles assets, net                             6,686        7,415
Deferred tax assets, non-current                    1,162        1,654
Deferred charge, non-current                        4,709        5,213
Restricted cash, non-current                        2,430        3,832
Other assets                                        537          820
Total assets                                        $129,720    $127,796
                                                                
LIABILITIES AND STOCKHOLDERS' EQUITY:                            
                                                                
Current liabilities:                                             
Accounts payable                                    $2,934      $5,496
Accrued expenses                                    6,211        10,595
Deferred revenue, current                           1,148        3,700
Income tax payable                                  --          148
Notes payable, current                              28,114       19,129
Other current liabilities                           1,286        1,003
Total current liabilities                           39,693       40,071
                                                                
Notes payable, non-current                          29,812       33,722
Deferred revenue, non-current                       6,490        7,093
Deferred tax liability, non-current                 2,632        2,627
Other liabilities                                   1,296        1,253
Total liabilities                                   79,923       84,766
                                                                
Stockholders' equity:                                            
Preferred stock, $0.01 par value; 5,000,000 shares
authorized at September 30, 2013 and December 31,                
2012;
no shares issued and outstanding at September 30,   --          --
2013 and December 31, 2012
Class A common stock, $0.01 par value; 270,000,000
shares authorized at September 30, 2013 and                      
December 31, 2012;
42,389,346 and 41,964,905 shares issued and
outstanding at September 30, 2013 and December 31,  423          420
2012, respectively
Additional paid-in capital                          65,758       62,521
Accumulated other comprehensive income              15,763       16,166
Treasury stock, at cost; 524,792 and 457,030 shares (2,313)      (1,977)
Accumulated deficit                                 (29,834)     (34,100)
Total stockholders' equity                          49,797       43,030
Total liabilities and stockholders' equity          $129,720    $127,796



Sucampo Pharmaceuticals, Inc.
Key Segment Information (unaudited)
                                                              
                                                              
(In thousands)                   Americas  Europe      Asia       Consolidated
Three Months Ended September 30,                               
2013
Research and development revenue $2,027  $--      $--     $2,027
Product royalty revenue          13,595   --        --       13,595
Product sales revenue            170      17         5,191     5,378
Co-promotion revenue             --      --        --       --
Contract and collaboration       141      12         10        163
revenue
Total revenues                   15,933   29         5,201     21,163
Cost of goods sold               3,389    4          2,874     6,267
Gross profit                     12,544   25         2,327     14,896
Research and development         2,467    1,088      919       4,474
expenses
Depreciation and amortization    309      47         8         364
Other operating expenses         8,893    1,646      563       11,102
Income (loss) from operations    875      (2,756)    837       (1,044)
Interest income                  18       2          --       20
Interest expense                 --      (417)      (44)      (461)
Other non-operating expense, net 6        95         (150)     (49)
Income (loss) before income      $899    $(3,076)  $643     $(1,534)
taxes
Capital expenditures             $9      $4        $--     $13
                                                              
Three Months Ended September 30,                               
2012
Research and development revenue $665    $72       $--     $737
Product royalty revenue          13,890   --        --       13,890
Product sales revenue            --      --        --       --
Co-promotion revenue             730      --        --       730
Contract and collaboration       141      (15)       13        139
revenue
Total revenues                   15,426   57         13        15,496
Cost of goods sold               --      --        --       --
Gross profit                     15,426   57         13        15,496
Research and development         2,239    2,543      833       5,615
expenses
Depreciation and amortization    122      242        10        374
Other operating expenses         9,677    1,161      322       11,160
Income (loss) from operations    3,388    (3,889)    (1,152)   (1,653)
Interest income                  65       3          --       68
Interest expense                 --      (556)      (40)      (596)
Other non-operating expense, net 34       165        (191)     8
Income (loss) before income      $3,487  $(4,277)  $(1,383) $(2,173)
taxes
Capital expenditures             $41     $--      $--     $41
                                                              
Nine Months Ended September 30,                                
2013
Research and development revenue $16,288 $--      $--     $16,288
Product royalty revenue          37,271   --        --       37,271
Product sales revenue            277      37         10,680    10,994
Co-promotion revenue             61       --        --       61
Contract and collaboration       424      34         32        490
revenue
Total revenues                   54,321   71         10,712    65,104
Cost of goods sold               3,465    12         5,980     9,457
Gross profit                     50,856   59         4,732     55,647
Research and development         6,446    4,307      3,775     14,528
expenses
Depreciation and amortization    543      548        26        1,117
Other operating expenses         27,368   3,374      2,743     33,485
Income (loss) from operations    16,499   (8,170)    (1,812)   6,517
Interest income                  54       8          1         63
Interest expense                 --      (1,326)    (123)     (1,449)
Other non-operating expense, net (9)      (169)      1,954     1,776
Income (loss) before income      $16,544 $(9,657)  $20      $6,907
taxes
Capital expenditures             $40     $110      $3       $153
                                                              
Nine Months Ended September 30,                                
2012
Research and development revenue $5,878  $74       $466     $6,418
Product royalty revenue          36,521   --        --       36,521
Product sales revenue            --      --        --       --
Co-promotion revenue             3,253    --        --       3,253
Contract and collaboration       424      (30)       39        433
revenue
Total revenues                   46,076   44         505       46,625
Cost of goods sold               --      --        --       --
Gross profit                     46,076   44         505       46,625
Research and development         6,250    5,405      2,547     14,202
expenses
Depreciation and amortization    366      709        30        1,105
Other operating expenses         32,475   2,576      916       35,967
Income (loss) from operations    6,985    (8,646)    (2,988)   (4,649)
Interest income                  105      12         1         118
Interest expense                 --      (1,656)    (124)     (1,780)
Other non-operating expense, net 67       82         578       727
Income (loss) before income      $7,157  $(10,208) $(2,533) $(5,584)
taxes
Capital expenditures             $293    $3,445    $--     $3,738

CONTACT: Sucampo Pharmaceuticals, Inc.
         Silvia Taylor
         Senior Vice President, Investor Relations, PR, and
         Corporate Communications
         1-240-223-3718
         staylor@sucampo.com

Sucampo Logo